Stock listing

BOATS:EXEL Exelixis, Inc. Stock

US listing (BOATS) of Exelixis, Inc. · home listing NASDAQ:EXEL

Follow Exelixis, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:EXEL

$62.68 USD +0.45 (+0.7%)

Close on Oct 19, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:EXEL

Since Jul 6, 2026 +12.9% · daily closes, Jul 6, 2026 – Oct 19, 2026, adjusted for splits
Day range
$61.67 – $62.81 USDOct 19, 2026
Volume
1.93M sharesOct 19, 2026
Market value
$15.53B USDAt the close on Oct 19, 2026 · price × 247.8M shares outstanding
Exelixis, Inc. logo
Ticker
BOATS:EXEL
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
BOATS
Currency
USD

What changed lately

Calls

Upcoming

  • Exelixis (NASDAQ:EXEL) Q3 2026 Earnings Call

    Thu, Oct 29, 2026 · 5:00 PM ET

    Register

Replays

  • Exelixis (NASDAQ:EXEL) Q2 2026 Earnings Call

    Wed, Aug 05, 2026 · 5:00 PM ET

    Watch Transcript

  • Exelixis (NASDAQ:EXEL) Q1 2026 Earnings Call

    Tue, May 05, 2026 · 5:00 PM ET

    Watch Transcript

  • Exelixis (NASDAQ:EXEL) Q4 2025 Earnings Call

    Tue, Feb 10, 2026 · 5:00 PM ET

    Watch Transcript

Latest news

Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026

Oct 15, 2026

Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories

Aug 31, 2026

Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Aug 5, 2026

Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026

Jul 22, 2026

Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer

Jun 22, 2026

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026

May 30, 2026

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June

May 27, 2026

Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types

May 21, 2026

Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer

May 19, 2026

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May

May 7, 2026

All Exelixis, Inc. news

Decks

Exelixis, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
24 in the last 12 months · 238 in all · newest Oct 15, 2026 · oldest 2019
Calls
23 calls with a replay · 23 with a transcript · latest Aug 5, 2026
Decks
9 decks · latest Aug 5, 2026

Where Exelixis, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:EXEL · Home listingNASDAQUnited StatesUSD
gettex:EX9gettexGermanyEUR
LS Exchange:936718LS ExchangeGermanyEUR
Tradegate:EX9TradegateGermanyEUR
Lang & Schwarz:936718Lang & SchwarzGermanyEUR
LSE:0IJOLSEUnited KingdomUSD
Frankfurt:EX9FrankfurtGermanyEUR
Milan:1EXELMilanItalyEUR
B3:E2XE34B3BrazilBRL
BOATS:EXEL · This pageBOATSUnited StatesUSD
Stuttgart:EX9StuttgartGermanyEUR
BX Swiss:EX9BX SwissSwitzerlandCHF
Dusseldorf:EX9DusseldorfGermanyEUR
Hamburg:EX9HamburgGermanyEUR
Munich:EX9MunichGermanyEUR

Log in to ask 6ix AI your own questions about Exelixis, Inc.